Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Britta A. McFerran"'
Autor:
Paul A. Zavorskas, Britta A. McFerran, Howard C. Dittrich, Edward G. Jablonski, Leslie Anderson, Anne L. Killam, Paige M. Mehlhaff, Jeffrey John Miller, Yigal Greener, Cindy Burrascano
Publikováno v:
International Journal of Toxicology. 18:49-63
OPTISON, an agent being developed as an intravenous (IV) ultrasound contrast agent, consists of a suspension of octafluoro-propane(OFP)-containing albumin microspheres. The distribution and elimination of the albumin component and the elimination kin
Autor:
Roberta M. Hunt, Gary L. Bales, Yigal Greener, Teri Kuvelas, Howard C. Dittrich, Britta A. McFerran
Publikováno v:
Journal of the American Society of Echocardiography. 8:465-474
A new intravenously administered ultrasound contrast agent was studied in eight dogs during intermittent coronary artery occlusion. The area of the myocardial contrast defect was compared with that of the acute wall motion abnormality induced by coro
Autor:
Yigal Greener, Britta A. McFerran, Amy Bloom, Howard C. Dittrich, Jack Maniquis, Kenneth J. Widder, Anne L. Killam
Publikováno v:
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine. 17(6)
The current study was designed to provide a sensitive in vivo model to maximize the potential bioeffects (measured by hemolysis) of B-mode ultrasound energy in combination with FS069 (Optison). B-mode ultrasound energy was delivered to anesthetized m
Autor:
Mary T. Kuvelas, Britta A. McFerran, Anthony G. Vallance, Yigal Greener, Patrick Rafter, Anne L. Killam, Howard C. Dittrich
Publikováno v:
Journal of the American College of Cardiology. 27:127
Publikováno v:
Journal of the American College of Cardiology. (2):204A
In order for myocardial contrast echocardiography to become clinically useful, ultrasound contrast agents must result in reproducible opacification. We therefore studied a new agent capable of producing myocardial opacification when given intravenous